1	Perf	ormance of empirical and model-based classifiers for
2	dete	cting sucrase-isomaltase inhibition using the <sup>13</sup> C-sucrose
3	brea	th test
4 5	Au Chi	<b>thors:</b> Hannah Van Wyk <sup>1</sup> , Gwenyth O. Lee <sup>2</sup> , Robert J. Schillinger <sup>3,4</sup> , ristine A. Edwards <sup>4</sup> , Douglas J. Morrison <sup>3</sup> , Andrew F. Brouwer <sup>1,*</sup>
6 7	1.	Department of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, 48109, MI, United States.
8	2.	Rutgers Global Health Institute, Rutgers University, 112 Paterson St. New Brunswick, NJ 08901
9 10	3.	Scottish Universities Environmental Research Centre (SUERC), University of Glasgow, Rankine Avenue, East Kilbride, G750QF, United Kingdom.
11 12	4.	School of Medicine, Dentistry and Nursing, University of Glasgow, New Lister Building, Alexandra Parade, Glasgow G31 2ER, United Kingdom.
13		*Corresponding author: brouweaf@umich.edu
14		
15		

#### Abstract 16

17 **Background:** Environmental enteric dysfunction (EED) is a syndrome characterized by epithelial

18 damage including blunting of the small intestinal villi and altered digestive and absorptive capacity

which may negatively impact linear growth in children. The <sup>13</sup>C-sucrose breath test (<sup>13</sup>C-SBT) has 19

been proposed to estimate sucrase-isomaltase (SIM) activity, which is thought to be reduced in EED. 20

21 We previously showed how various summary measures of the <sup>13</sup>C-SBT breath curve reflect SIM

22 inhibition. However, it is uncertain how the performance of these classifiers is affected by test 23

duration.

24 Methods: We leveraged SBT data from a cross-over study in 16 adults who received 0, 100, and 750

25 mg of Reducose, a natural SIM inhibitor. We evaluated the performance of a pharmacokinetic-model-

26 based classifier,  $\rho$ , and three empirical classifiers (cumulative percent dose recovered at 90 minutes

27 (cPDR90), time to 50% dose recovered, and time to peak dose recovery rate), as a function of test

28 duration using receiver operating characteristic curves. We also assessed the sensitivity, specificity,

29 and accuracy of consensus classifiers.

30 **Results:** Test durations of less than 2 hours generally failed to accurately predict later breath curve

31 dynamics. The cPDR90 classifier had the highest area-under-the-curve and, by design, was robust to

32 shorter test durations. For detecting mild SIM inhibition,  $\rho$  had a higher sensitivity.

33 **Conclusions:** We recommend SBT tests run for at least a 2-hour duration. Although cPDR90 was the

34 classifier with highest accuracy and robustness to test duration in this application, concerns remain

35 about its sensitivity to misspecification of CO<sub>2</sub> production rate. More research is needed to assess

36 these classifiers in target populations.

Keywords: environmental enteric dysfunction, <sup>13</sup>C-sucrose breath test, sucrase-isomaltase inhibition, 37 38 mechanistic model, classifier

39

## 40 Introduction

41 Environmental enteric dysfunction (EED) is characterized by atrophy of the small intestinal villi,

42 resulting in increased intestinal permeability and nutrient malabsorption. It is thought to be highly

43 prevalent among people in low- and middle-income countries who lack access to improved water,

sanitation, and hygiene [1] and are therefore highly exposed to enteric pathogens [2,3]. EED is

thought to play a central role in impaired linear growth (stunting) in infants and young children,[4]

- 46 which impacts about 150 million children globally.
- 47 EED may be detected through the identification of histological features in small intestinal biopsies

48 [5]. However, biopsies are invasive, require specialist skills and settings and are ethically questionable

49 in sub-clinical EED, limiting the ability to accurately, efficiently, and inexpensively identify EED,

50 especially in low-resource settings [6]. The most widely accepted non-invasive test, the

51 lactulose:mannitol/rhamnose dual sugar urine absorption test, is time-consuming to administer and

results may be inconsistent across laboratory platforms [7]. The  ${}^{13}$ C sucrose breath test ( ${}^{13}$ C-SBT) has

been proposed as an alternative [8]. The <sup>13</sup>C-SBT is a stable-isotope breath test in which an individual

<sup>54</sup> ingests a dose of non-radioactive, <sup>13</sup>C-labeled sucrose substrate, which is digested, absorbed, and

metabolized, appearing on the breath as  ${}^{13}$ CO<sub>2</sub>. The  ${}^{13}$ C-SBT is intended to assess the activity of

56 intestinal enzyme sucrase-isomaltase (SIM), a glucosidase enzyme that catalyzes the hydrolysis of

57 carbohydrates [9]. Expression of SIM increases towards the tips of intestinal villi and therefore its

activity is thought to be diminished in a damaged intestine [10-12]. Slower recovery of the tracer

59 breath  ${}^{13}$ CO<sub>2</sub> therefore indicates reduced gut enzyme metabolic function.

Although the  ${}^{13}$ C-SBT is attractive as a potential, non-invasive test of EED, it also has some

61 limitations, which are common across <sup>13</sup>C breath tests. Traditional measures used to interpret breath

62 tests consist of empirically fitting a parametric curve to the percent dose recovery rate (PDRr) of

 $^{13}$ CO<sub>2</sub> on the breath, and calculating summary statistics, such as the cumulative percent dose

recovered at 90 minutes (cPDR90), the time to peak PDRr  $(T_{peak})$ , or the time to 50 percent dose

65 recovered  $(T_{50})$  [13, 14]. However, these empirical measurements do not necessarily capture the

underlying biological processes giving rise to the PDRr curve, and thus may be confounded by

67 multiple aspects of the metabolism, some of which are unrelated to gut function. To address this

68 concern we developed a mechanistic, pharmacokinetic model whose parameters represent the

69 underlying biological processes occurring in the metabolism of the <sup>13</sup>C-labeled sucrose tracer [15]. A

model-based diagnostic  $\rho$  performed comparably to the highest-performing summary statistics in

71 identifying experimentally induced sucrase-isomaltase inhibition in healthy adults [16].

72 In this analysis, we revisit these experiments to assess how the performance of the four highest

performing classifiers, namely  $\rho$ , cPDR90,  $T_{peak}$  and  $T_{50}$ , depend on the test duration. While

experiments establishing and evaluating the SBT have used test durations of 4-8 hours [8, 15], there is

a strong need to reduce the testing burden on participants, particularly for the target population of

- infants and children under 5 years. Additionally, because cPDR90,  $T_{peak}$ ,  $T_{50}$ , and  $\rho$  capture different
- information about the breath curve, we will determine if consensus classifiers combining two or more
- 78 classifiers can produce a more reliable diagnosis. In this research, we address these research gaps by
- assessing the accuracy of SBT curve projections based on shorter test duration, the performance of
- 80 these three classifiers across test durations, and performance of consensus classifiers.

#### 81 Methods

#### 82 **Data**

The <sup>13</sup>C-SBT breath curves used in this study were obtained in a crossover study conducted in 83 84 Glasgow, United Kingdom, as previously described [16]. In brief, eighteen healthy adults were 85 recruited to complete three breath test experiments under different experimental conditions designed 86 to simulate different degrees of SIM inhibition. In this analysis, we only use data from the 16 87 participants who completed all three breath tests. The participants consisted of 8 female and 8 male 88 participants with a mean age of 24.2 (SD= 5.0) and mean BMI of 24.5 (SD = 5.2). Participants were instructed to follow a low <sup>13</sup>C diet for the three days preceding the experiments and to fast 89 90 for eight hours prior to the test. In the first experiment, participants ingested 25 mg (0.84 mmol 91 13C) of highly enriched sucrose (≥99 atom% enriched; Sigma-Aldrich) to complete a baseline test. 92 Breath samples were collected every 15 minutes for 4 hours into 12mL Exetainer breath-sample vials (Labco, United Kingdom). The relative difference in parts per thousand between the ratio 93  $R_s = [^{13}C]/[^{12}C]$  in the sample and the ratio ( $R_{std}$ ) of the laboratory CO<sub>2</sub> standard (calibrated to the 94 95 international calibration standard, VPDB, R = 0.0112372) were determined by isotope ratio mass 96 spectrometry (IRMS, AP-2003, Manchester, United Kingdom). Details on how this was converted to 97 percent dose recovery rate are described in previous publications [15]. In the remaining experiments, 98 participants were given in a random order either 100 and 750 mg of Reducose® (Phynova Group Ltd., 99 Oxford, UK), a mulberry leaf extract (MLE) containing 5% 1-Deoxynojirimycin (an active  $\alpha$ -100 glucosidase inhibitor) immediately prior to ingesting the 25 mg sucrose. Mulberry leaf extract has been shown to function as an intestinal SIM inhibitor, thus it is expected to induce similar <sup>13</sup>CO<sub>2</sub> 101 102 excretion patterns to those that would be observed in patients with EED. The low dose of 100 mg 103 Reducose was given to induce mild SIM inhibition, and the high dose of 750 mg was given to induce 104 severe inhibition. Investigators received written informed consent from all participants and the study 105 design was approved by the University of Glasgow College of Medical Veterinary and Life Sciences 106 Research Ethics Committee (Application Number: 200190155).

#### 107 Mechanistic Model

108 In previous work [15], we developed a mechanistic, compartmental differential equation model that

- 109 captured <sup>13</sup>C-SBT breath curve dynamics and was practically identifiable, i.e., had parameters that
- 110 could be uniquely estimated from data. In this model, the breath curve dynamics can be approximated
- 111 as a combination of a gamma-distributed process with pharmacokinetic rate parameter  $\rho/2$  and shape
- 112 parameter 2 and an exponentially distributed process with rate parameter  $\pi \rho$ . Because of the
- 113 limitations of only observing the breath, the specific metabolic processes that these model processes
- represent are unknown *a priori*. In previous work [16], we demonstrated that both sucrase-isomaltase
- inhibition and the difference between fructose and glucose in the transport to and metabolism by the
- 116 liver were reflected in the gamma-distributed process. In the model, we also account for the fraction
- 117 of <sup>13</sup>C that is exhaled,  $\kappa$ , as opposed to being secreted in urine or sequestered in adipose tissue.
- 118 When  $\pi \neq 1$ , there is a closed-form solution for PDRr,

$$y(t) = \frac{100\kappa\pi\rho}{(1-\pi)^2} \left( e^{-\pi\rho t} + \left( (\pi-1)\rho t - 1 \right) e^{-\rho t} \right), \tag{1}$$

and the cPDR is given by

$$Y(t) = 100\kappa \left(1 - \frac{e^{-\pi\rho t} + ((\pi - 1)\rho t + \pi - 2)\pi e^{-\rho t}}{(1 - \pi)^2}\right) . \#(2)$$

120

- 121 The classifiers we consider in this analysis are all obtained directly from the above equations:
- 122 cPDR90 = Y(90),  $T_{peak}$  = argmax<sub>t</sub> y(t),  $T_{50}(\omega) = \{t \mid Y(t) = \frac{Y(\omega)}{2}\}$ , where  $\omega$  is the test length, and  $\rho$ 123 is the model-based classifier based on previous work [16]. Note that the definition of  $T_{50}$  used here, 124 50% of the cumulative percent dose recovered at test length  $\omega$ , is different from previous work, [15] 125 which defined it as time to recovery of 50% of the dose given. We use our definition here because 126 most test participants do not recover 50% of the full dose over the testing period, especially in the 127 case of mild-to-severe SIM inhibition.

128

#### 129 **Parameter estimation**

- 130 We estimated the parameter set  $\theta = \{\rho, \pi\rho, \kappa\}$  corresponding to the best fit model by minimizing the
- 131 negative log-likelihood (NLL), given by

$$NLL(\theta) = \frac{n}{2}\log(2\bar{\pi}) + \frac{n}{2}\log(\sigma^2) + \frac{1}{2\sigma^2}\sum_i (y(\theta; t_i) - z_i)^2, \#(3)$$

where  $y(\theta; t_i)$  is the value of the modeled PDR at time  $t_i$ , n is the number of data points,  $\bar{\pi}$  is the mathematical circle constant,  $\sigma$  is the standard deviation previously estimated to be 0.555 from bestfit curves [15], and  $t_i$  is the time at which measurement  $z_i$  was taken. In the case where the peak PDRr is not observed during the testing period, which was common among the 750 mg Reducose samples,  $\pi\rho$  and  $\kappa$  are not identifiable. In this case, we added a penalty of size 0.1 $\kappa$  onto the NLL to force the optimizer to select lower values of  $\kappa$ . This forces the optimizer to choose larger values of  $\pi\rho$  that generate more realistic PDRr curves that do not extend over unrealistically long periods of time.

## 139 Analytic Approach

140 The three objectives of this analysis were to 1) compare the accuracy of model projections as a

141 function of test duration, 2) compare the performance of cPDR,  $T_{peak}$ ,  $T_{50}$ , and  $\rho$ , as a function of test

duration, and 3) assess the performance of consensus classifiers that combine two or more of the

- single classifiers. In this analysis, we examined test durations of 60, 90, 120, and 240 minutes. The
- 144 following analysis plan outlines our approach:

145 1.) Comparing model fits for 60-, 90-, 120-, and 240-minute duration tests. For each participant j, we

146 estimated  $\hat{\theta}_{60,j}, \hat{\theta}_{90,j}, \hat{\theta}_{120,j}$ , and  $\hat{\theta}_{240,j}$ , corresponding to the nine parameters that minimized the

147 NLL for the baseline, 100 mg Reducose, and 750 mg Reducose breath curves, assuming that we

only had the data from the first 60, 90, 120, and full 240 minutes, respectively. Then, to compare

the model fits for the 60-, 90-, and 120-minute tests to the full dataset, we simulated the model for

- 150 240 minutes using each parameter set and calculated the NLL from each simulation against the
- 151 full 240-minute data.
- 152 2.) Comparing receiver operator characteristic (ROC) curves for  $\rho$ , cPDR,  $T_{50}$  and  $T_{peak}$  for 60-, 90-
- 153 , 120-, and 240-minute duration tests. We first noted that breath test curves that are initially
- slower (have a lower PDRr) also sustain a higher PDRr longer than the faster curves, allowing
  them to "catch up" to cumulative dose recovered of faster curves over time, which have a higher
- 156 maximum PDRr, but a sharper curve around the peak. Therefore, the value of cPDR at a later time

157 may be a less effective classifier than the value at an earlier time, and the cPDR with the highest

dialogistic capability should be near the median  $T_{peak}$ . Thus, we first determined which cPDR

159 classifier (cPDR60, cPDR90, cPDR120, or cPDR240) resulted in the most accurate classification

160 using  $\hat{\theta}_{240,j}$ . As discussed in the results, we selected cPDR90. Then, we simulated the model for

161 each parameter set  $\theta_{60,j}$ ,  $\theta_{90,j}$ ,  $\theta_{120,j}$ , and  $\theta_{240,j}$ , and estimated  $\rho$ , cPDR90,  $T_{50}$  and  $T_{peak}$  in each

- 162 case. We generated receiver operator characteristic (ROC) curves (which plot the true positive
  163 rate against the false positive rate as the classification threshold is varied) for all 12 combinations
  164 of test duration and classifier, for each of 4 groupings of the MLE experiments, corresponding to
- 165 different clinical scenarios:
- 166

1. Detection of any SIM inhibition (baseline versus either 100 or 750 mg MLE),

- 167 2. Distinguishing between severe SIM inhibition vs none-to-mild (baseline or 100 mg MLE
  168 versus 750 mg MLE),
- 169 3. Detection of mild SIM inhibition (i.e., baseline versus 100 mg MLE),
- 170 4. Detection of severe SIM inhibition (baseline versus 750 mg MLE).
- 171 The goal of the first two diagnostic groupings is to offer a single metric that captures the test's

ability to generate a binary diagnosis of SIM inhibition when the classifier takes any level of
inhibition as an input, as would be the case in real-world applications. The last two classifiers
assess the classifiers' ability to identify differences in each of the three groups. For each ROC

175 176

curve, we calculated the area under the curve (AUC) statistic, which represents the probability that a randomly selected positive sample is ranked as more likely to have SIM inhibition than a

177 randomly selected negative sample [17].

178 3.) Assessment of single and consensus classifiers. We assessed the accuracy, sensitivity, specificity, 179 and Matthew's correlation coefficient (MCC) of each classifier at their optimal thresholds (the 180 cutoff threshold that maximizes the sum of the sensitivity and specificity of the test [18]). The 181 MCC is an alternative accuracy measurement that is preferred for unbalanced datasets and has a 182 range of [-1,1] where 1 means perfect classification, 0 corresponds to a coin toss classifier, and -1 183 is perfect misclassification [19]. We further examined the accuracy, sensitivity, specificity, and 184 Matthew's correlation coefficient (MCC) of consensus classifiers consisting of each combination 185 of the individual metrics  $\rho$ , cPDR90,  $T_{50}$ , and  $T_{peak}$  at their optimal thresholds. To generate these 186 statistics for each participant in each experiment, we generated consensus diagnoses for each 187 participant based on each combination of the individual classifiers. For example, assuming that a 188 positive diagnosis of SIM inhibition is defined by *both*  $\rho$  and cPDR90 ( $\rho \cap$  cPDR90) indicating 189 inhibition or assuming that a positive diagnosis is defined by *either*  $\rho$  and cPDR90 ( $\rho \cup$  cPDR90) 190 indicating inhibition. We assessed this for each possible combination of three classifiers at a time. 191 For example, for  $\rho$ , cPDR90, and  $T_{50}$  that is:  $\rho$  only, cPDR90 only,  $T_{50}$  only,  $\rho \cap$  cPDR90,  $\rho \cap T_{50}$ , 192 cPDR90  $\cap$   $T_{50}$ ,  $\rho \cap$  cPDR90  $\cap$   $T_{50}$ ,  $\rho \cup$  cPDR90,  $\rho \cup$   $T_{50}$ , cPDR90  $\cup$   $T_{50}$ , and a majority rules 193 classifier. For the majority rules classifier, a positive diagnosis was generated if at least two of the 194 individual classifiers are positive. To compare consensus classifier performances for each of the 195 three MLE doses, we generated this result for each of the same four comparison groups outlined 196 in step 2. We repeated this for the 60-, 90-, and 120-minute test lengths to assess classifier 197 robustness to decreased data. 198

## 199 **Results**

200 *Comparing model fits for 60-, 90-, 120-, and 240-minute tests.* Projections from fitting the model only 201 to the first 60 minutes of the data were consistently poor fits for the later data (illustrative examples 202 given in Fig. 1a, with full results in Fig S1 in the SI appendix). For the 60-min test duration, random 203 variations present in each data point had a higher influence on the model fit than it did with longer test 204 periods, causing model trajectories in hours 1–4 to be heavily impacted by these fluctuations. 205 Additionally, the inability to observe the peak PDRr in the first hour—particularly for the 750 mg 206 group—meant that  $\pi\rho$  and  $\kappa$  were unidentifiable at this test duration, severely limiting the model's

- 207 inferential ability for later hours. While the 90-minute test duration generally improved the fit
- 208 somewhat, the improvement was not consistent across participants, and many curves fit to 90 minutes
- 209 were poorly predictive of later dynamics. When comparing the NLLs between the models fit to data
- from each test length (Figure 1b), we found substantial heterogeneity in the impact of test length on
- 211 model fit, depending on the participant. The fits at shorter tests lengths were typically better in
- 212 participants for whom the peak PDRr was reached within the respective test length (see Fig S1 in the
- SI appendix). In general, the projections from curve fit to the data from the first 120 minutes are very
- similar to the curves fit to the full data, with some outliers. In the following sections, we assessed how
- the improvement in model fit is reflected in the diagnostic capability of the test.

216

Figure 1: a) Model best fits for 60-, 90-, 120-, and 240-minute test durations for two study

- 218 participants b) Boxplot of negative log-likelihoods (NLLs), a measure of how well the model fits the
- 219 data, for each test duration, with larger values indicating poorer fit. Plots for all participants are given
- in Fig S1 in the SI appendix.
- 221
- We also plot the value of each classifier for each participant and test duration across the three MLE doses to visualize each classifier's sensitivity to MLE dosage (Fig. 2). The plots for cPDR90 (Fig. 2a) show that this classifier has the strongest distinction between the lowest two doses (i.e., baseline or 100 mg MLE) and the 750 mg dose; however, the distinction between the baseline and 100 mg MLE dose is minor. By contrast, the figure for  $\rho$  (Fig. 2b) shows a better separation between the value of  $\rho$ and MLE dose, indicating that this classifier may be more sensitive to detecting lower MLE doses, which represent mild SIM inhibition.
- 229
- Figure 2: Classifier values for 60-, 90-, 120-, and 240-minute <sup>13</sup>C-sucrose breath test durations for baseline, 100, and 750 mg doses of Reducose®, a mulberry leaf extract (MLE) that acts as a sucraseisomaltase inhibitor for (a) cPDR90, (b)  $\rho$ , (c)  $T_{peak}$ , and (d)  $T_{50}$ .
- 233
- 234 Comparing ROC curves for  $\rho$ , cPDR, time to 50% dose recovered ( $T_{50}$ ), and time to peak ( $T_{peak}$ ) for
- 235 60-, 90-, 120-, and 240-minute duration tests. We found that cPDR90 and cPDR60 outperformed
- 236 cPDR120, and cPDR240 in ROC curves (Fig. S3). Prior literature has used cPDR90, so, for
- 237 consistency, we selected cPDR90 as the cPDR classifier to compare to  $\rho$ ,  $T_{50}$  and  $T_{peak}$ . Our ROC
- 238 curves for baseline versus either 100 or 750 mg MLE (Fig 3, blue) and baseline or 100 mg MLE
- versus 750 mg MLE (Fig 3, yellow) showed that cPDR90 had the highest AUC for each test length
- and comparison group. The cPDR90 classifier also maintained the same AUC (0.99) for each test
- length for 0 or 100 mg v. 750 mg and only saw a slight decrease in the AUC for the other comparison

- group (0.79 at 240 minutes versus 0.77 at 60 minutes). The ROC curves corresponding to baseline
- 243 versus 100 mg (Fig S2) show that  $\rho$  outperforms cPDR90 for distinguishing mild SIM inhibition from
- none (AUC ranges: 0.61-0.66 for  $\rho$  and 0.55-0.60 for cPDR90). However, because  $\rho$  was not as
- accurate at distinguishing severe inhibition from no inhibition in these data (AUC range: 0.58-0.93),
- its AUC is always below the AUCs corresponding to cPDR90 in Fig 3. Additional ROC curves
- assuming the data is available at 15 min for hours 0-1, every 30 min for hours 1-4 is available in the
- 248 SI appendix as an additional sensitivity analysis (Fig. S4).
- 249 Assessment of consensus classifiers. Table 1 shows the results of the consensus classifiers including
- 250 cPDR90,  $\rho$ , and  $T_{50}$ , which were the three highest performing classifiers according to Fig. 2. The
- 251 consensus classifiers including  $T_{peak}$  are available in the Supplementary Material, (Tables S1 through
- S4). Consistent with the results from the ROC curves, the performance statistics of the consensus
- classifiers (Table 1) show that cPDR90 alone has the highest accuracy and MCC for each of the four
- 254 Reducose dose comparison groupings. However, for sensitivity, cPDR90 is outperformed by  $\rho$  and  $T_{50}$
- for the baseline versus 100 mg group, and by  $\rho \cup$  cPDR90 for 0 versus 750 mg and 0/100 versus 750
- 256 mg. For the shorter test durations, cPDR90 continues to be the best classifier for all comparison
- groups for the 120-minute test length (Table S1). However,  $\rho$  and  $T_{50}$  surpass cPDR90 by the 90- and
- 258 60-minutes lengths for the baseline versus 100 mg and 0 v 100/750 mg comparison groups (Tables S1
- and S2). The consensus classifiers also perform better than the individual classifiers at these shorter
- 260 test durations. For example, at the 60-minute test duration, cPDR  $\cap$   $T_{peak}$  and  $\rho \cap$  cPDR  $\cap$   $T_{peak}$
- had the highest accuracy and MCC for the baseline versus 100 mg group (Table S1).
- Figure 3: ROC curves for 60-, 90-, 120-, and 240-minute <sup>13</sup>C-sucrose breath test durations for
- baseline versus either 100 or 750 mg doses of Reducose®, a mulberry leaf extract (MLE) that acts as
- a sucrase-isomaltase inhibitor (blue), and baseline or 100 mg MLE versus 750 mg MLE (orange).

**Table 1:** Accuracy, sensitivity, specificity, and Matthew's Correlation Coefficient (MCC) of

consensus metrics for the 240-minute duration test.

	ρ	cPDR	T 50	$\rho \cap$	$\rho \cap$	cPDR	$\rho \cup$	$\rho \cup$	$\rho \cup$	cPDR	Majority
				cPDR	$T_{50}$	$\cap T_{50}$	cPDR ∪	cPDR	T 50	$\cup T_{50}$	rules
							T 50				
Accuracy											
0 v. 100 mg	0.66	0.72	0.66	0.72	0.66	0.72	0.66	0.66	0.66	0.66	0.66
0 v. 750 mg	0.88	0.97	0.91	0.91	0.91	0.91	0.94	0.94	0.88	0.97	0.91
0/100 v. 750 mg	0.85	0.98	0.92	0.94	0.92	0.94	0.90	0.9	0.85	0.96	0.92
0 v. 100/750 mg	0.71	0.81	0.62	0.73	0.62	0.62	0.79	0.79	0.71	0.81	0.73
Sensitivity											
0 v. 100 mg	0.94	0.81	0.94	0.81	0.94	0.81	0.94	0.94	0.94	0.94	0.94
0 v. 750 mg	0.88	0.94	0.81	0.81	0.81	0.81	1.00	1.00	0.88	0.94	0.81
0/100 v. 750 mg	0.88	0.94	0.81	0.81	0.81	0.81	1.00	1.00	0.88	0.94	0.81
0 v. 100/750 mg	0.72	0.91	0.44	0.72	0.44	0.44	0.91	0.91	0.72	0.91	0.72
Specificity											
0 v. 100 mg	0.38	0.63	0.38	0.63	0.38	0.62	0.38	0.38	0.38	0.38	0.38
0 v. 750 mg	0.88	1.00	1.00	1.00	1.00	1.00	0.88	0.88	0.88	1.00	1.00
0/100 v. 750 mg	0.84	1.00	0.97	1.00	0.97	1.00	0.84	0.84	0.84	0.97	0.97
0 v. 100/750 mg	0.69	0.63	1.00	0.75	1.00	1.00	0.56	0.56	0.69	0.62	0.75
MCCs											
0 v. 100 mg	0.38	0.45	0.38	0.45	0.38	0.45	0.38	0.38	0.38	0.38	0.38
0 v. 750 mg	0.75	0.94	0.83	0.83	0.83	0.83	0.88	0.88	0.75	0.94	0.83
0/100 v. 750 mg	0.69	0.95	0.81	0.86	0.81	0.86	0.80	0.80	0.69	0.91	0.81
0 v. 100/750 mg	0.39	0.56	0.45	0.45	0.45	0.45	0.51	0.51	0.39	0.56	0.45

267

268

## 269 **Discussion**

270 In this analysis, we leveraged a mechanistic model to compare the performance of traditional,

271 empirical classifiers (i.e., cPDR90,  $T_{50}$  and  $T_{peak}$ ) of <sup>13</sup>C-SBT breath test to that of a mechanistic,

- 272 pharmacokinetic model-based classifier. We found that, under typical data variation, 60-minute
- 273 duration tests were insufficient to adequately project breath trajectories, primarily due to limited
- ability to observe some of the post-peak PDRr trajectory in these time lengths (Figure 1). Thus, we
- 275 recommend <sup>13</sup>C-SBT future protocols use a 120-minute or longer test duration. For the <sup>13</sup>C-SBT, test
- durations up to 240 minutes saw enhanced accuracy and improvement in the performance of the
- 277  $T_{50}$ ,  $T_{peak}$  and model-based classifier, but the ability to estimate SIM activity from a shorter-duration
- test supports the wider use of the <sup>13</sup>C-SBT for gut dysfunction research and, potentially, for future
- 279 clinical usage. However, other <sup>13</sup>C breath tests may have different recommended durations if the
- 280 distribution of peak PDRr is different for a different isotopic tracer, so further study of potential
- tracers could identify a substrate with a further reduced testing burden.
- 282 Our results from the classifier performance comparison show that cPDR90 was the best classifier (by
- AUC) at each test length, compared to  $\rho$ ,  $T_{50}$ , and  $T_{peak}$  (Fig. 2). These results suggest that, even
- though cPDR is not directly measuring the underlying biological mechanisms, slow cumulative
- 285 recovery of the breath is highly informative. We also found that the consensus classifiers generally
- 286 performed worse than the individual ones, largely because cPDR90 was highly accurate on its own for
- this population. However, as we see in Eq 2, the cumulative percent dose recovery is highly
- 288 dependent on  $\kappa$ , the fraction of tracer that is excreted through the breath. Hence, the performance of
- 289 cPDR will be highly sensitive to variations in this fraction or, as we previously showed [15], to
- 290 misestimation of the production rate of  $C0_2$ ,  $V_{CO2}$ , which is estimated based on body size. As a result,
- associations between cPDR and demographic or anthropometric variables may be introduced through
- 292 differential bias In  $V_{CO2}$  estimates. This limits the application of the cPDR to the <sup>13</sup>C-as a test of EED
- in young children, because poorer growth is posited to be a key consequence of EED. We will explore
- anthropometric and demographic associations with breath curve dynamics in future work). Hence, we
- 295 caution against taking our results as evidence that cPDR90 is the only classifier needed. Additionally,

```
296 we note that both \rho and T_{peak} outperform cPDR90 for model sensitivity (Table 1) and for
```

distinguishing the 100 mg dose from baseline (Fig. S2). Currently, it is unknown whether SIM

- inhibition in typical a case of EED is more similar to the inhibition induced by the 100 mg MLE doseor the 750 mg dose.
- 300 We found that some classifiers were quite accurate at shorter test lengths or even had a higher AUC at
- 301 shorter test lengths. For example, the  $T_{peak}$  AUC for 0 mg v. 100 mg has a higher AUC (0.68) when
- 302 generated from the 60-minute data as opposed to the 240-minute data (AUC = 0.61). However, this
- 303 result does not necessarily indicate that those classifiers were robust to a shorter test length. Rather,

this behavior is a data artifact: the curves estimated at the shorter test lengths are often poor fits to the

- 305 full breath curve (Fig S1), and thus they happen to have better classifier performance only by
- 306 accident. The same classifier might perform drastically worse on a different dataset for that test
- 307 duration. This phenomenon is not a limitation of our analysis but a limitation of short-duration breath
- 308 tests, and it has implications for future studies. Participants do not always complete the full breath
- 309 collection protocol, but researchers may want to include the data that were collected. We advise
- 310 having a clear exclusion criterion in <sup>13</sup>C-SBT studies for participants who do not complete at least 90-
- 311 min of breath collection.
- 312 The primary strength of this study is the crossover study design. The experimental design artificially
- 313 induced SIM inhibition in the study participants, making the comparison between experiments
- unconfounded by other factors that would be likely present in cases and controls from separate
- 315 populations. However, because the data is from healthy adult participants for whom SIM was
- 316 experimentally inhibited, the performance of the classifiers may be different from the target
- 317 population, i.e., children in low-resource settings, which means that the external generalizability may
- 318 be limited. In addition, the small samples size makes the results more sensitive to random
- 319 measurement error. For the <sup>13</sup>C-SBT to move from being a specialized research tool to wider
- 320 useability, further research that includes a larger sample size and inclusion of study participants from
- the target population will be needed. Our results facilitate this work by suggesting a shortened, 120-
- 322 minute test duration, that may be more feasible for infants and young children compared to the prior,
- 323 standard 4-hour test.

## 324 Conclusion

- 325 We assessed the performance of two empirical classifiers, cPDR90, T<sub>50</sub>, and T<sub>peak</sub>, and one model-326 based classifier,  $\rho$  for the SBT over different test lengths. Based on curves fit to different test lengths, 327 we recommend that <sup>13</sup>C-SBT protocols include 120-min or longer test durations and that participants 328 who collect less than 90 min of breath be excluded. We found that, overall, cPDR90 was the most 329 accurate classifier in these data; however, limitations of this classifier include uncertainty around its 330 performance in the target population and lower sensitivity in detecting cases of mild SIM inhibition. 331 The model-based classifier  $\rho$  addresses both concerns because it is more reflective of the underlying 332 biological processes giving rise to the PDRr curves. We recommend multiple classifiers continue to be considered in future work assessing the performance of the <sup>13</sup>C-SBT as a diagnostic test of EED or 333 334 other dysfunctions that reduce SIM activity.
- 335
- 336
- 337

# 338 Author contributions

- 339 Conceptualization (of this analysis): AFB, GOL, DJM; Methodology: AFB, HVW; Investigation:
- 340 RJS, CAE, DJM; Formal Analysis: HVW; Visualization: HVW; Writing Original Draft: HVW;
- 341 Writing Review & Editing: AFB, GOL, HVW, DJM. Supervision: DJM (lab), AFB (analysis). All
- 342 authors read and approved the final manuscript.
- 343

# 344 Acknowledgements

- 345 This project was funded through the International Atomic Energy Agency (IAEA) coordinated
- research projects E4.10.16 and E430336, United States National Science Foundation (NSF) grant
- 347 DMS1853032, and United States National Institutes of Health (NIH) grant K01AI145080. The NSF
- and NIH were not involved in study design; collection, analysis, and interpretation of data; writing of
- 349 the report. The IAEA was involved in study design of the data collection. We also thank Dr. Mamane
- 250 Zeilani, Nutriset for part-funding of this work and Dr. Andrew Gallagher of Phynova Group Ltd for
- 351 the supply of Reducose for this study. The industry collaborators had no role in study design,
- 352 collection, analysis, interpretation of the data or writing of the report.

# 353 Conflict of Interest declaration

- 354 The authors declare that they have no conflicts of interest.
- 355

# 356 Data Availability Statement

- 357
- 358

## 359 **References**

- Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, et al. Environmental
   enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clinical Infectious
   Diseases. 2014;59(suppl 4):S207-12.
- Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an overview. Food and
   nutrition bulletin. 2015;36(1 suppl1):S76-87.
- Korpe PS, Petri WA. Environmental enteropathy: critical implications of a poorly understood
   condition. Trends in molecular medicine. 2012;18(6):328-36.
- Tickell KD, Atlas HE, Walson JL. Environmental enteric dysfunction: a review of potential
   mechanisms, consequences and management strategies. BMC medicine. 2019;17:1-9.
- Ta-Chiang Liu TC, VanBuskirk K, Ali SA, Kelly P, Holtz LR, Yilmaz OH. A novel
   histological index for evaluation of environmental enteric dysfunction identifies geographic specific features of enteropathy among children with suboptimal growth. PLoS Neglected
   Tropical Diseases. 2020; *14*(1), e0007975.
- 373 [6] Hodges P, Tembo M, Kelly P. Intestinal biopsies for the evaluation of environmental
  anteropathy and environmental enteric dysfunction. The Journal of Infectious Diseases.
  2021;224(Supplement 7):S856-63.
- [7] Lee GO, Kosek P, Lima AA, Singh R, Yori PP, Olortegui MP, et al. Lactulose: mannitol
  diagnostic test by HPLC and LC-MSMS platforms: considerations for field studies of
  intestinal barrier function and environmental enteropathy. Journal of pediatric
  gastroenterology and nutrition. 2014;59(4):544.
- Schillinger RJ, Mwakamui S, Mulenga C, Tembo M, Hodges P, Besa E, et al. 13C-sucrose
  breath test for the non-invasive assessment of environmental enteropathy in Zambian adults.
  Frontiers in Medicine. 2022;9:904339.
- Gorvel J, Ferrero A, Chambraud L, Rigal A, Bonicel J, Maroux S. Expression of
  sucraseisomaltase and dipeptidylpeptidase IV in human small intestine and colon.
  Gastroenterology. 1991;101(3):618-25.
- [10] Gupta SK, Chong SK, Fitzgerald JF. Disaccharidase activities in children: normal values and
   comparison based on symptoms and histologic changes. Journal of pediatric gastroenterology
   and nutrition. 1999;28(3):246-51.

389 390 391	[11]	Yu J, Ordiz MI, Stauber J, Shaikh N, Trehan I, Barnell E, et al. Environmental enteric dysfunction includes a broad spectrum of inflammatory responses and epithelial repair processes. Cellular and molecular gastroenterology and hepatology. 2016;2(2):158-74.
392	[12]	Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y, Hawkes JS, et al. 13C-sucrose
393 394		breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics. 2009;124(2):620-6.
395	[13]	Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, et al. Measurement of
396		gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test.
397		Gastroenterology. 1993;104(6):1640-7.
398	[14]	Maes B, Mys G, Geypens B, Evenepoel P, Ghoos Y, Rutgeerts P. Gastric emptying flow
399		curves separated from carbon-labeled octanoic acid breath test results. American Journal of
400		Physiology-Gastrointestinal and Liver Physiology. 1998;275(1):G169-75.
401	[15]	Brouwer AF, Lee GO, Schillinger RJ, Edwards CA, Wyk HV, Yazbeck R, et al. Mechanistic
402		inference of the metabolic rates underlying 13 C breath test curves. Journal of
403		Pharmacokinetics and Pharmacodynamics. 2023:1-12.
404	[16]	Brouwer AF, Lee GO, Van Wyk H, Schillinger RJ, Edwards CA, Morrison DJ. A model-
405		based 13C-sucrose breath test diagnostic for gut function disorders characterized by a
406		loss of sucrase-isomaltase enzymatic activity. The Journal of Nutrition. 2023
407	[17]	Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic
408		test evaluation. Caspian journal of internal medicine. 2013;4(2):627.
409	[18]	Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point.
410		Biometrical Journal: Journal of Mathematical Methods in Biosciences.
411		2005;47(4):458-72.
412	[19]	Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over F1
413		score and accuracy in binary classification evaluation. BMC genomics. 2020;21(1):113.





MLE dose 🟟 0 mg 🔯 100 mg 🖾 750 mg



🗕 0 mg v. 100/750 mg 💻 0/100 mg v. 750 mg